Olivier Bogillot

About Olivier Bogillot

Olivier Bogillot is a French executive known for his strong background at the intersection of healthcare, public policy, and the pharmaceutical industry. He serves as an independent director of Clariane SE, where he brings deep expertise in regulation, market access, institutional affairs, and the governance of health-related organizations. His appointment to Clariane’s board was proposed in 2025, replacing Jean-François Brin, with the aim of strengthening the group’s capabilities in healthcare, dependency care, and regulatory matters. He holds a PhD in Economics from the University of Lyon I, a master’s degree in Health Economics and Public Health, and a degree in Molecular Biology and Physiology. This unusual combination of scientific and economic training has shaped a career that bridges healthcare policy and corporate leadership. Earlier in his career, he held senior positions at Merck KGaA, Amgen, and Bristol-Myers Squibb, mainly focused on market access in France and across Europe. Those roles gave him a detailed understanding of healthcare systems, pricing and reimbursement discussions, and the pathways required to bring innovation to patients. In 2009, Bogillot joined the Île-de-France Regional Health Agency, and in 2011 he became an advisor at the French Presidency, focusing on health, dependency policy, and social policy. That institutional experience broadened his perspective beyond corporate affairs and placed him close to major public policy decisions affecting the health sector. He joined Sanofi in 2015 and went on to hold several key roles, including Executive Chief Global Policy Officer, Chief of Staff to the Chief Executive Officer, Chairman of Sanofi France, and later Head of North America General Medicines. Through these positions, he built substantial experience in strategy, public affairs, international management, and stakeholder engagement. He also served on the board of Leem, chaired the French federation of health industries and the strategic sector committee for health industries and technologies, and was a member of the Medef board as well as co-chair of its social protection committee. Overall, his profile reflects a rare blend of industrial leadership, policy expertise, and governance experience.